Synthesis and preclinical evaluation of novel ^99mTc-labeled PSMA ligands for radioguided surgery of prostate cancer.

ABSTRACT:

Background

Radioguided surgery (RGS) has recently emerged as a valuable new tool in the management of recurrent prostate cancer (PCa). After preoperative injection of a ^99mTc-labeled prostate-specific membrane antigen (PSMA) inhibitor, radioguided intraoperative identification and resection of lesions is facilitated by means of suitable γ-probes. First clinical experiences show the feasibility of RGS and suggest superiority over conventional lymph node dissection in recurrent PCa. However, commonly used [^99mTc]Tc-PSMA-I&S exhibits slow whole-body clearance, thus hampering optimal tumor-to-background ratios (TBR) during surgery. We therefore aimed to develop novel ^99mTc-labeled, PSMA-targeted radioligands with optimized pharmacokinetic profile to inc

SUBMITTER: Kunert JP 

PROVIDER: S-EPMC9842843 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature